Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Kaufman, Howard
Item TypeName
Academic Article A new mouse model for evaluating the immunotherapy of human colorectal cancer.
Academic Article Defining the critical hurdles in cancer immunotherapy.
Concept Immunotherapy, Active
Concept Immunotherapy, Adoptive
Concept Immunotherapy
Academic Article The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Academic Article Cancer immunotherapy trials: leading a paradigm shift in drug development.
Academic Article Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Academic Article Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Academic Article Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
Academic Article Combination immunotherapy: a road map.
Academic Article Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Academic Article Integrating oncolytic viruses in combination cancer immunotherapy.
Academic Article An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Academic Article Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy.
Academic Article Immunotherapy for Merkel cell carcinoma: a turning point in patient care.
Academic Article Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses.
Academic Article Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Academic Article Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Academic Article Cytokine therapy for cancer.
Academic Article Precision immunology: the promise of immunotherapy for the treatment of cancer.
Academic Article Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy.
Academic Article Imaging the immune response to monitor tumor immunotherapy.
Academic Article Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
Academic Article A phase I trial of intra lesional RV-B7.1 vaccine in the treatment of malignant melanoma.
Academic Article TroVax(®) vaccine therapy for renal cell carcinoma.
Academic Article Optimal management of metastatic melanoma: current strategies and future directions.
Academic Article Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.
Academic Article Finding gold in tumour immunotherapy.
Academic Article Poxviruses as vectors for cancer immunotherapy.
Academic Article Immune oncology, immune responsiveness and the theory of everything.
Academic Article Chemokines in tumor immunotherapy.
Academic Article Oncolytic viruses: focusing on the tumor microenvironment.
Academic Article Viral vaccines for cancer immunotherapy.
Academic Article Management of Metastatic Melanoma in 2018.
Academic Article Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.
Academic Article Oncolytic virus immunotherapy for melanoma.
Academic Article Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen.
Academic Article Chemokines and cancer.
Academic Article Intratumoral Approaches for the Treatment of Melanoma.
Academic Article The tumour microenvironment and implications for cancer immunotherapy.
Academic Article The role of poxviruses in tumor immunotherapy.
Academic Article Unleashing the therapeutic potential of oncolytic viruses.
Academic Article Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.
Academic Article Innovative treatments for pancreatic cancer.
Academic Article Immunotherapy for pancreatic cancer: current concepts.
Academic Article Adjuvant therapy for malignant melanoma.
Academic Article Carcinoembryonic antigen (CEA) presentation and specific T cell-priming by human dendritic cells transfected with CEA-mRNA.
Academic Article High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
Academic Article Targeting costimulatory pathways for tumor immunotherapy.
Academic Article Rational Combination Immunotherapy: Understand the Biology.
Academic Article Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide.
Academic Article Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
Academic Article Oncolytic viruses: a new class of immunotherapy drugs.
Academic Article Immune system versus tumor: shifting the balance in favor of DCs and effective immunity.
Academic Article Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
Academic Article Gene therapy with poxvirus vectors.
Academic Article Prostate-specific antigen vaccines for prostate cancer.
Academic Article The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Academic Article Combination Immunotherapy for Melanoma.
Academic Article Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy.
Academic Article Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.
Academic Article Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.
Academic Article Immunotherapy for melanoma.
Academic Article CEA-based vaccines.
Academic Article Poxvirus vaccines for cancer and HIV therapy.
Academic Article Biomarkers for Immunotherapy: Current Developments and Challenges.
Academic Article Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.
Academic Article IFN-? cancer immunotherapy: new kid on the block.
Academic Article Avelumab: is it time to get excited?
Academic Article Next generation approaches for tumor vaccination.
Academic Article Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
Academic Article Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Academic Article Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.
Academic Article Two roads for oncolytic immunotherapy development.
Academic Article MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Academic Article Oncolytic viruses: a new class of immunotherapy drugs.
Academic Article The promise of Immuno-oncology: implications for defining the value of cancer treatment.
Academic Article Oncolytic Immunotherapy.
Academic Article Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Academic Article Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma.
Academic Article Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.
Academic Article Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.
Academic Article Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Academic Article Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer.
Academic Article Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit.
Academic Article Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
Search Criteria
  • Immunotherapy
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.